Nectin-4 is an immunoglobulinlike cell adhesion molecule that contributes to tumor aggressiveness and immune evasion in pancreatic ductal adenocarcinoma (PDAC). Its high and selective expression on pancreatic cancer cells, together with the clinical efficacy of nectin-4-targeted antibody–drug conjugates in other solid tumors, establishes nectin-4 as a compelling therapeutic target in PDAC.

Gastroesophageal junction (GEJ) adenocarcinoma is an increasingly common cancer with complex biology and poor prognosis. The treatment strategy for locally advanced tumors involves multimodal treat...

Current biomarkers for diagnosis and prognosis prediction in gastric (GC) and gastroesophageal junction (GEJ) cancer have limited accuracy, and the role of soluble immune checkpoints is unknown. In th...

Cancer does not develop overnight. It can take decades for cancer-promoting changes in the genome to eventually lead to the formation of a malignant tumor. Researchers at the German Cancer Research Ce...

Meeting overview details for AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research - Emerging Science Driving Transformative Solutions

Perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) is a standard therapy for resectable gastric and gastroesophageal junction adenocarcinomas, but recurrence rates remain hig...

First-line treatment with anlotinib plus penpulimab significantly improves the outcomes of patients with unresectable hepatocellular carcinoma relative to sorafenib.

The German Cancer Congress is the oldest, most important and largest scientific congress on oncology in German-speaking countries.

Exploratory biomarker analyses of the phase 3 CheckMate 649 trial show that in patients with advanced gastroesophageal cancer, KRAS alterations were associated with greater overall survival (OS) benef...

Chang et al. provide a comprehensive single-cell spatial transcriptomic map of esophageal squamous cell carcinoma, revealing that invasive epithelial cells promote cancer progression by forming a pro-tumor niche with cancer-associated fibroblasts (CAFs).…

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage pancreatic cancer patients.

British Journal of Cancer - Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration

IL-33 induces tertiary lymphoid structures.

Sears and colleagues found that ongoing replication stress pathways and T cell clonal responses differentiate liver and lung recurrence and are associated with different clinical outcomes in the conte...

An enzyme called MICAL2 promotes tumor growth and metastasis in the most common form of pancreatic cancer, according to a new study by UC San Diego School of Medicine researchers.